Multiple iNOS inhibitors have been developed36, and using these for the treatment of pancreatic cancer may help to prevent immune suppression and support adoptive T-cell therapies and cancer vaccines targeting the neoantigen landscape. Here, NOS2 is linked to familial pancreatic carcinoma.